June 19, 2018
Chicago, June 19, 2018 – SAMDI Tech Inc., the industry’s leading provider of label-free drug discovery solutions, is pleased to announce it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop the first cell-based and label-free, high-throughput assay of specific enzyme activities.
Funding is provided by the National Center for Advancing Translational Sciences (NCATS) of the NIH for Phase I of the project. SBIR grants are awarded to companies that demonstrate scientific excellence and technological innovation in their project proposals.
“This award will enable us to expand SAMDI Tech’s leadership in label-free, high-throughput drug discovery solutions,” said Dr. Zack Gurard-Levin, chief scientific officer at SAMDI Tech and principal investigator on the grant. “Additionally, developing a new cell-based assay for specific enzyme activities will allow us to contribute to the advancement of health care and drug discovery research.”
To receive funding, NIH award winners go through a competitive application and review process. Recipient projects have been identified by the NIH as unique and of high scientific caliber and are determined relevant to public health needs and within NIH priorities.
About SAMDI Tech
SAMDI Tech, Inc. delivers better, faster, label-free assay development, high-throughput screening and peptide substrate discovery solutions for early-stage drug candidate selection. Our highly skilled team believes in results and uses proprietary industry-leading, label-free SAMDI (Self-Assembled Monolayer Desorption Ionization) technology to deliver decision-making data fast. Learn more about SAMDI Tech at www.samditech.com.